 |
|
|
| |
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/r +
Dasabuvir + RBV for HCV/HIV Co-Infection
|
| |
| |
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
David Wyles1, Michael Saag2, Roger Trinh3, Jacob Lalezari4, Oluwatoyin Adeyemi5, Laveeza Bhatti 6, Amit Khatri3, Jennifer R King3, Yiran B Hu3, Rolando Viani3, Nancy S Shulman3, Peter Ruane7
1University of California San Diego, La Jolla, California, United States; 2Center for AIDS Research, University of Alabama at Birmingham, Birmingham, Alabama, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Quest Clinical Research, San Francisco, California, United States; 5Ruth M Rothstein CORE Center, Chicago, Illinois, United States; 6AIDS Healthcare Foundation, Beverly Hills, California, United States; 7Ruane Medical & Liver Health Insti tute, Los Angeles, California, United States
|
| |
|
|
|
|
|
